Free Trial

Australia halts AstraZeneca vaccine for most people under 50

In this image made from video, Australian Prime Minister Scott Morrison speaks during a news conference in Canberra, Australia, Thursday, April 8, 2021. Australia on Thursday become the latest country to restrict use of the AstraZeneca vaccine by recommending that it not be given to people under age 50. (SBS via AP)

CANBERRA, Australia (AP) — Australia on Thursday become the latest country to restrict use of the AstraZeneca vaccine by recommending that it not be given to people under age 50.

The announcement came after Australian drug regulators held a series of urgent meetings earlier in the day. The recommendation came after the European Medicines Agency said it had found a “possible link” between the shot and the rare blood clots, though regulators in the United Kingdom and the European Union emphasized that the benefits of receiving the vaccine continue to outweigh the risks for most people.

Prime Minister Scott Morrison said he'd received a series of recommendations from an advisory group on Thursday night, and that chief among them was that the Pfizer vaccine should now be adopted as the preferred vaccine for people aged under 50.

Morrison said the recommendations were made with an abundance of caution due to the rare but serious side effects, which have mostly been associated with younger people.

“We’ve been taking the necessary precautions based on the best possible medical advice,” Morrison said. “It has not been our practice to jump at shadows.”

The Australian Technical Advisory Group on Immunisation also recommended that people under 50 who had already received their first AstraZeneca shot should proceed with getting their second shot, as the medical advice indicated the rare blood clots only develop after the first dose.

The group said that only when the benefit clearly outweighs the risk should an initial AstraZeneca shot be given to someone under 50.

Healthcare workers under 50 who were due to receive the AstraZeneca vaccine will now be prioritized for the Pfizer vaccine, which will likely delay the inoculation process.

Indeed, under Australia’s vaccine strategy, most people were due to receive the AstraZeneca vaccine.

Opposition politicians said the European agency's findings highlighted the danger in Australia failing to secure vaccine deals with other suppliers.

The move in Australia came after British authorities recommended that the AstraZeneca vaccine not be given to adults under 30 where possible. Several other countries have also imposed limits.

Such restrictions are closely watched since the vaccine, which is cheaper and easier to store than many others, is critical to global immunization campaigns and is a pillar of the U.N.-backed program known as COVAX that aims to get vaccines to some of the world’s poorest countries.

Should You Invest $1,000 in Pfizer Right Now?

Before you consider Pfizer, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.

While Pfizer currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report
Like this article? Share it with a colleague.

Companies Mentioned in This Article

CompanyMarketRankâ„¢Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Pfizer (PFE)
4.977 of 5 stars
$25.56-0.2%6.73%18.52Hold$28.55
Compare These Stocks  Add These Stocks to My Watchlist 

Featured Articles and Offers

Recent Videos

Don’t Miss These Top 3 Defense Stocks Set To Gain
Triple-Digit Gains: These 4 Nuclear Stocks Have Even More Upside Ahead
3 Made in America Stocks Under $20 You Need to See!

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines